α1-blockers for the reduction of ureteric stent-related symptoms: A systematic review and meta-analysis

Experimental and Therapeutic Medicine

Volumn 11, Issue 2, 2016, Pages 660-668

  Zhang, Peng ^a   Hu, Wan Li ^a   Cheng, Bei ^a   Cheng, Long ^a   Zeng, Yang Jun ^a   Wang, Gang ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Quality of life; Ureteral stent; 1 blockers

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; ASSESSMENT OF HUMANS; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; DIZZINESS; HEADACHE; HUMAN; HYPOTENSION; META ANALYSIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; QUALITY OF LIFE; SCORING SYSTEM; SYSTEMATIC REVIEW; URETER DISEASE; URETERAL STENTING; URETERIC STENT SYMPTOMS QUESTIONNAIRE;

EID: 84951009926     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2942     Document Type: Article

References (35)

1. Zimskind PD, Fetter TR and Wilkerson JL: Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 97: 840-844, 1967.
2. Nabi G, Cook J, N'Dow J and McClinton S: Outcomes of stenting after uncomplicated ureteroscopy: Systematic review and meta-analysis. BMJ 334: 572, 2007.
3. Pengfei S, Yutao L, Jie Y, Wuran W, Yi D, Hao Z and Jia W: The results of ureteral stenting after ureteroscopic lithotripsy for ureteral calculi: A systematic review and meta-analysis. J Urol 186: 1904-1909, 2011.
4. Al-Awadi KA, Abdul Halim H, Kehinde EO and Al-Tawheed A: Steinstrasse: A comparison of incidence with and without J stenting and the effect of J stenting on subsequent management. BJU Int 84: 618-621, 1999.
5. Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr and Timoney AG: Ureteral stent symptom questionnaire: Development and validation of a multidimensional quality of life measure. J Urol 169: 1060-1064, 2003.
6. Keeley FX Jr and Timoney AG: Routine stenting after ureteroscopy: Think again. Eur Urol 52: 642-644, 2007.
7. Damiano R, Autorino R, Esposito C, Cantiello F, Sacco R, de Sio M and D'Armiento M: Stent positioning after ureteroscopy for urinary calculi: The question is still open. Eur Urol 46: 381-387, discussion 387-388, 2004.
8. Makarov DV, Trock BJ, Allaf ME and Matlaga BR: The effect of ureteral stent placement on post-ureteroscopy complications: A meta-analysis. Urology 71: 796-800, 2008.
9. Dellis A, Joshi HB, Timoney AG and Keeley FX Jr: Relief of stent related symptoms: Review of engineering and pharmacological solutions. J Urol 184: 1267-1272, 2010.
10. Lingeman JE, Preminger GM, Goldfischer ER and Krambeck AE; Comfort Study Team: Assessing the impact of ureteral stent design on patient comfort. J Urol 181: 2581-2587, 2009.
11. Krambeck AE, Walsh RS, Denstedt JD, Preminger GM, Li J, Evans JC and Lingeman JE; Lexington Trial Study Group: A novel drug eluting ureteral stent: A prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent. J Urol 183: 1037-1042, 2010.
12. Tadros NN, Bland L, Legg E, Olyaei A and Conlin MJ: A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal: A prospective, randomised, double-blind, placebo-controlled trial. BJU Int 111: 101-105, 2013.
13. Dellis AE, Keeley FX Jr, Manolas V and Skolarikos AA: Role of α -blockers in the treatment of stent-related symptoms: A prospective randomized control study. Urology 83: 56-61, 2014.
14. Kuehhas FE, Miernik A, Sharma V, Sevcenco S, Javadli E, Herwig R, Szarvas T, Schoenthaler M, Schatzl G and Weibl P: A prospective evaluation of pain associated with stone passage, stents, and stent removal using a visual analog scale. Urology 82: 521-525, 2013.
15. Shalaby E, Ahmed AF, Maarouf A, Yahia I, Ali M and Ghobish A: Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-j stent-related lower urinary symptoms. Adv Urol 2013: 752382, 2013.
16. Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A and Varkarakis IM: Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology 67: 35-39, 2006.
17. Campschroer T, Zhu Y, Duijvesz D, Grobbee DE and Lock MT: Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev 4: CD008509, 2014.
18. Furukawa TA, Barbui C, Cipriani A, Brambilla P and Watanabe N: Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 59: 7-10, 2006.
19. Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D and Barrowman NJ: A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol 59: 342-353, 2006.
20. Lim KT, Kim YT, Lee TY and Park SY: Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts. Korean J Urol 52: 485-488, 2011.
21. Martov AG, Maksimov VA, Ergakov DV, Miroshnikov VM, Asfandiiarov FR and Kalashnikov ES: Tamsulosin administration for prophylaxis and treatment of stent-related symptoms. Urologiia: 3-8, 2010. (In Russian).
22. Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM and D'Armiento M: Effect of tamsulosin in preventing ureteral stent-related morbidity: A prospective study. J Endourol 22: 651-656, 2008.
23. Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K and Monga M: Alfuzosin to relieve ureteral stent discomfort: A prospective, randomized, placebo controlled study. J Urol 181: 170-176, 2009.
24. Park SC, Jung SW, Lee JW and Rim JS: The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol 23: 1913-1917, 2009.
25. Wang CJ, Huang SW and Chang CH: Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: A prospectively randomized study. Urol Res 37: 147-152, 2009.
26. Lee SJ, Yoo C, Oh CY, Lee YS, Cho ST, Lee SH, Yang DY, Lee SK and Cho JS: Stent position is more important than α-blockers or anticholinergics for stent-related lower urinary tract symptoms after ureteroscopic ureterolithotomy: A prospective randomized study. Korean J Urol 51: 636-641, 2010.
27. Navanimitkul N and Lojanapiwat B: Efficacy of tamsulosin 0.4 mg/day in relieving double-J stent-related symptoms: A randomized controlled study. J Int Med Res 38: 1436-1441, 2010.
28. Mokhtari G, Shakiba M, Ghodsi S, Farzan A, Heidari Nejad S and Esmaeili S: Effect of terazosin on lower urinary tract symptoms and pain due to double-J stent: A double-blind placebo-controlled randomized clinical trial. Urol Int 87: 19-22, 2011.
29. Elnashar A and Shelbaia A: Role of tamsulosin in improving double-j ureteric stent-related symptoms. Afr J Urol 17: 111-114, 2011.
30. Nazim SM and Ather MH: Alpha-blockers impact stent-related symptoms: A randomized, double-blind, placebo-controlled trial. J Endourol 26: 1237-1241, 2012.
31. Kuyumcuoglu U, Eryildirim B, Tuncer M, Faydaci G, Tarhan F and Ozgül A: Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms. Can Urol Assoc J 6: E234-E237, 2012.
32. Tehranchi A, Rezaei Y, Khalkhali H and Rezaei M: Effects of terazosin and tolterodine on ureteral stent related symptoms: A double-blind placebo-controlled randomized clinical trial. Int Braz J Urol 39: 832-840, 2013.
33. Yakoubi R, Lemdani M, Monga M, Villers A and Koenig P: Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol 186: 928-934, 2011.
34. Lamb AD, Vowler SL, Johnston R, Dunn N and Wiseman OJ: Meta-analysis showing the beneficial effect of α-blockers on ureteric stent discomfort. BJU Int 108: 1894-1902, 2011.
35. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L and Sterne JA; Cochrane Bias Methods Group; Cochrane Statistical Methods Group: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343 (oct18 2): d5928, 2011.